West Pharmaceutical stock heads into the open after a 0.7 percent dip
Published on 09/11/2026 at 05:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
West Pharmaceutical stock closed at USD 338.79 on the New York Stock Exchange on September 9, 2026, down 0.7% from the prior session. Compared with a broadly steady S&P 500 close that day, this left West Pharmaceutical lagging the large-cap benchmark in the last completed session.
September 9, 2026 in numbers
West Pharmaceutical Services Inc. (ISIN US9523901012, NYSE: WST) ended the September 9, 2026 session at USD 338.79 after trading between an intraday high near USD 340 and a low in the mid-330s, according to New York Stock Exchange quote data reported in a recent market wrap. The move represented a decline of 0.7% on the day, with the stock giving back part of its earlier advance seen earlier in the week. This level left the shares some distance below typical analyst price targets around the USD 370 range cited in coverage on September 10, 2026, underscoring that the stock traded below prevailing sell-side expectations at the latest close, as MarketBeat reported.
Intraday trading on September 9, 2026 was accompanied by insider and governance developments that remained in focus. On September 10, 2026, filings summarized by StockTitan highlighted that a senior executive exercised options and sold shares around an average price of USD 340.81, signaling active use of equity awards near the recent trading range. In addition, a Form 4 detailed on September 10, 2026 showed option grants to the chief executive officer with a strike price of USD 337.75 per share and a long-dated expiry, as reported by StockTitan, tying management incentives closely to levels near the latest close.
Conference takeaways and insider focus today
Looking to today ahead of the open on September 11, 2026, investors in West Pharmaceutical stock are likely to weigh recent commentary from management alongside the insider activity disclosed this week. At a Wells Fargo healthcare conference held on September 10, 2026, executives discussed growth expectations and indicated a full-year outlook in the 10% to 11% range, according to a transcript published by Investing.com. That conference guidance provides fresh context for the stock’s valuation and may frame discussions around demand trends and margin performance as trading resumes today.
Analyst and media coverage on September 10, 2026 also highlighted that West Pharmaceutical shares were trading at forward valuation multiples in the mid-30s, with some commentators flagging the name as profitable but carrying warning signs at current prices, as Barchart noted. Together with the insider sales and option grants disclosed on September 10, 2026, these perspectives give the market several fresh data points to digest when West Pharmaceutical stock heads into today’s session.
